Friday, July 31, 2026

How the U.S., Japan, and South Korea’s MOC on SMR Could Transform Energy Security in Asia

South Korea, the U.S., and Japan signed a MOC to boost small modular reactors in the Indo-Pacific, enhancing energy security and cooperation.

How LG CNS and FuriosaAI Are Revolutionizing AI Infrastructure for the Public Sector

LG CNS partners with FuriosaAI to enhance AI services using neural processing units, targeting the public AI transformation market.

Samsung Biologics CEO John Rim Poised for Third Term: What This Means for the Global CDMO Market in 2026

John Rim of Samsung Biologics aims for a third term, leading record growth and expansion into next-gen therapies amid global challenges.

Tag: cancer

North KoreaKoreaKimMilitaryAISouth KoreamarketrelationsInternational

GIST’s Breakthrough in Gene Diagnosis: A Game-Changer for Cancer and Infectious Disease Testing

GIST unveils a versatile genetic diagnostic platform, enhancing detection across diseases while simplifying design and improving efficiency.

LG Chem’s FMC-220: A Breakthrough Cancer Drug Targeting the p53 Y220C Mutation

LG Chem secures exclusive rights to FMC-220, a cancer drug targeting the p53 Y220C mutation, aiming for Phase 1 trials.

GC Cell’s CAR-NK: Revolutionizing Solid Tumor Treatment with New Patent

GC Cell has patented an immunotherapy targeting solid tumors using its CAR-NK platform, aiming for safer, cost-effective treatments.

HLB’s Liraglutide: A Game-Changer in Cholangiocarcinoma Treatment with FDA Priority Review

HLB's Elevar Therapeutics receives FDA Priority Review for lirafugratinib, a promising treatment for cholangiocarcinoma with a 47% response rate.

1 Trillion KRW Donation: How the Lee Kun-hee Legacy is Transforming Infectious Disease Research in Korea

Samsung's donation aids childhood cancer and rare diseases, funding research and infrastructure to combat infectious diseases in South Korea.

Unlocking Cancer Treatment: How TXN12923 Targets ULK1 for Enhanced Drug Sensitivity

Txinno Bioscience to present TXN12923, a novel ULK1 targeted protein degrader, at AACR, aiming to enhance cancer treatment efficacy.

Coreline Soft Provides AI Lung Cancer Screening Solution to Charité University Hospital in Germany

Coreline Soft implements AI lung cancer screening solutions at Charité University Hospital, enhancing diagnostic efficiency and consistency.

Unlocking Cancer Treatment: ABL206 and ABL209’s Promising Non-Clinical Data Revealed at AACR

ABL Bio will present preclinical data for its ADCs ABL206 and ABL209 at AACR 2023, showcasing promising anti-cancer efficacy.

How Rasmotinib and PHI-501 Could Revolutionize Cancer Treatment: Insights from Bio Europe Spring 2026

Pharos iBio showcases its cancer treatments at Bio Europe Spring 2026, seeking global partnerships for Rasmotinib and PHI-501.

Nesuparib: A Game-Changer in Cancer Treatment? Key Findings from AACR 2026

Onconic Therapeutics' Nesuparib shows promising results against small cell lung and pancreatic cancers, highlighting its competitive edge.

New Breakthrough: HER2 Positive Stomach Cancer Treatment with Dual Targeted Therapy Shows 81% Tumor Size Reduction

A study reveals that combining trastuzumab deruxtecan and pertuzumab significantly reduces tumor size in HER2-positive gastric cancer.

HLB Pep Signs Deal with Japan’s ReproCELL to Supply Customized Neoantigen Peptides — The Future of Precision Medicine?

HLB PEP partners with Reprocell to supply customized neo-antigen peptides for personalized cancer treatment, targeting global markets.

Unlocking Treatment Potential: GI-102 and Pasritamig Clinical Trial Insights

GI Innovation has filed an IND application for a clinical trial on a combination therapy for metastatic prostate cancer in South Korea and the U.S.

Breakthrough Cancer Drug BAL0891: Key Findings to be Revealed at AACR 2026

SillaJen's cancer drug BAL0891 will be presented at the AACR 2026 conference, highlighting its effects on gastric and breast cancer models.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.